Table 1.
Patient demographics at baseline
| Number of Patients | 148 |
| Sex (Female/Male), n | 68/80 |
| Age, y | 48.6±15.1 |
| Age at start smoking, y | 18.4±3.9 |
| Level of smoking, pack/years | 24.9±16.4 |
| Daily number of cigarettes (cig/day) | 19.2±8.6 |
| Mild smoker (0–9) | 6 (4.8) |
| Moderate smoker (10–19) | 44 (29.7) |
| Heavy smoker (>20) | 98 (66.2) |
| FNAQ, points | 5.1±2.2 |
| low grade addiction (0–3) | 41 (27.7) |
| Intermediate grade addiction (4–6) | 70 (47.2) |
| high grade addiction (7–10) | 37 (25.0) |
| CAT scores, points | 19.8±9.0 |
| Pulmonary function test | |
| FEV1, L | 2.22±1.17 |
| FEV1, % | 67.9±29.1 |
| FVC, L | 3.17±1.38 |
| FVC, % | 81.24±27.97 |
| FEV1/FVC, % | 67.49±12.80 |
| PEF | 3.22±2.17 |
| PEF (%) | 43.64±23.25 |
| FEF25–75, L | 2.37±1.05 |
| FEF25–75, % | 53.38±26.04 |
| COPD GOLD status | |
| Stage-0 | 65/148 – (43.9) |
| Stage-I | 19/148 – (12.8) |
| Stage-II | 21/148 – (14.1) |
| Stage-III | 17/148 – (11.4) |
| Stage-IV | 26/148 – (17.5) |
| Smoking cessation treatments | |
| Only NRT | 50 (75.7) |
| NRT + Varenicline | 36 (24.3) |
| Patients with initial inhaler treatment | 43 (29.0) |
| Successfull smoking cessation at 3-M | 100 (67.5) |
| Quitters at 12-M | 68 (45.9) |
| Non-quitters at 12-M | 80 (54.1) |
Data are presented mean±SD or n (%).
FEV1: a forced expiration volume in 1 s; FVC: forced vital capacity; PEF: peak expiratory flow; FEF25–75: forced expiratory flow between 25% and 75% of vital capacity; COPD GOLD: Global Initiative for Chronic Obstructive Lung Disease; FNAQ: Fagerström Nicotine Addiction Questionnaire; CAT: chronic obstructive lung disease assessment test; M: month; L: liter; NRT: nicotine replacement treatment